Monitor future Form 4 filings for any open-market purchases or sales by Dr. Roberts, which could signal her conviction in the company's prospects. No immediate trading signal from this initial filing.
Price Chart
Executive Summary
Eiry Roberts, M.D., the new Chief Medical Officer of Neurocrine Biosciences, filed a Form 3 initial statement of beneficial ownership, disclosing 51,331 shares of common stock held directly and 50,146 shares held jointly, along with various stock options and restricted stock units. This is a routine insider filing with no material impact on the company's operations or financials.
Key Facts
- Eiry Roberts appointed Chief Medical Officer of Neurocrine Biosciences as of September 28, 2026.
- Dr. Roberts directly owns 51,331 shares of common stock and 50,146 shares are held in a joint trust.
- Dr. Roberts holds multiple non-qualified and incentive stock options with exercise prices ranging from $79.02 to $136.69, expiring between 2030 and 2036.
- Dr. Roberts holds 16,129 restricted stock units (RSUs) across five grants, vesting through February 2029.
Financial Impact
No financial impact; routine initial ownership disclosure for a new officer.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001727606-26-000004 |
| Document: 0001727606-26-000004-index-headers.html | 0001727606-26-000004 |
| Document: 0001727606-26-000004-index.html | 0001727606-26-000004 |
| Document: 0001727606-26-000004.txt | 0001727606-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 1d ago | Institutional Cluster | $147.19 | awaiting T+60 | awaiting T+60 | $145.62 (−1.07%) |
Oct 15, 2026 13d ago | SC 13G/A | $136.95 | awaiting T+60 | awaiting T+60 | $145.62 (+6.33%) |
Oct 15, 2026 13d ago | Institutional Cluster | $136.95 | awaiting T+60 | awaiting T+60 | $145.62 (+6.33%) |
Oct 7, 2026 21d ago | 3 | $141.25 | awaiting T+60 | awaiting T+60 | $145.62 (+3.09%) |
Sep 15, 2026 6w ago | Insider Cluster | $149.50 | awaiting T+60 | awaiting T+60 | $145.62 (−2.60%) |
Jul 13, 2026 15w ago | Insider Cluster | $172.04 $143.47 | ▼ −16.61% | ▼ −19.98% | $145.62 (−15.36%) |
Jul 9, 2026 15w ago | Press Release | $177.11 $144.21 | ▼ −18.58% | ▼ −21.21% | $145.62 (−17.78%) |
Jun 9, 2026 20w ago | Insider Cluster | $160.86 $158.35 | ▼ −1.56% | ▼ −8.14% | $145.62 (−9.47%) |
Jun 8, 2026 20w ago | Insider Cluster | $165.24 $157.79 | ▼ −4.51% | ▼ −8.32% | $145.62 (−11.87%) |
Jun 8, 2026 20w ago | Insider Cluster | $165.24 $157.79 | ▼ −4.51% | ▼ −8.32% | $145.62 (−11.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers